Molecular profiling of cerebral gliomas distinguishes biologically distinct tumor groups and provides prognostically relevant information beyond histological classification and IDH1/2 mutation status. We performed Methylation profiling of primary tumor samples from 122 patients with cerebral gliomas with WHO grade II and grade III tumors.
<br>
<br>
Accompanying publication is available <a href="https://pubmed.ncbi.nlm.nih.gov/29888966/", target="_blank">here</a>.